Wikipedia

Sodium phenylbutyrate/ursodoxicoltaurine

(Redirected from AMX0035)

Sodium phenylbutyrate/ursodoxicoltaurine, also known as sodium phenylbutyrate/taurursodiol and sold under the brand names Albrioza and Relyvrio, is a fixed-dose combination medication used for the treatment of amyotrophic lateral sclerosis (ALS).[2][4][6] It contains sodium phenylbutyrate and ursodoxicoltaurine (taurursodiol).[2]

Sodium phenylbutyrate/ursodoxicoltaurine
Combination of
Sodium phenylbutyratePan-histone deacetylase inhibitor
Ursodoxicoltaurinebile acid
Clinical data
Trade namesAlbrioza, Relyvrio
Other namesAMX0035
AHFS/Drugs.comMultum Consumer Information
MedlinePlusa623014
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

The most common adverse reactions experienced with sodium phenylbutyrate/ursodoxicoltaurine include diarrhea, abdominal pain, nausea and upper respiratory tract infection.[7]

Sodium phenylbutyrate/ursodoxicoltaurine acts by blocking apoptotic pathways in the mitochondria and in the endoplasmic reticulum.[6] Sodium phenylbutyrate is a chemical chaperone that helps proteins maintain their normal conformation, preventing aggregation that may lead to cell death.[6] Ursodoxicoltaurine improves mitochondrial energy production.[6]

The combination was approved for medical use in Canada as Albrioza, in June 2022,[1][2][8] and in the United States, as Relyvrio, in September 2022.[5][9][7] The European Union's drug regulators refused to approve it, citing concerns about effectiveness.[10] In April 2024, the manufacturer announced that it is withdrawing the medication from the US and Canadian markets, due to it failing a key phase III clinical trial. [11]

Medical uses

edit

Sodium phenylbutyrate/ursodoxicoltaurine is indicated for the treatment of amyotrophic lateral sclerosis (ALS).[2][4][5]

History

edit

In the Phase II/III CENTAUR clinical trial, sodium phenylbutyrate/ursodoxicoltaurine (AMX0035) increased survival times for ALS patients.[12][13][14][15][16] The Phase II PEGASUS clinical trial found that the drug was safe and tolerated by patients with Alzheimer's disease.[17]

The efficacy of sodium phenylbutyrate/ursodoxicoltaurine for the treatment of ALS was demonstrated in a 24-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study.[7][18] Compared to members of the 137-adult cohort that received a placebo medication, those randomly assigned to treatment with sodium phenylbutyrate/ursodoxicoltaurine showed a slower rate of declining daily functioning and longer overall survival.[7]

In September 2022, the United States Food and Drug Administration (FDA) approved Amylyx Pharmaceuticals' application for Relyvrio's approval under the priority review and orphan drug programs.[7]

In March 2024, Amylyx Pharmaceuticals announced that its Phase III PHOENIX clinical trial of 664 American and European adults followed over 48 weeks showed no statistically significant difference in the functioning of ALS patients that were randomly assigned to treatment with Relyvrio, as compared to those receiving a placebo drug.[19]

Society and culture

edit
edit

The FDA Peripheral and Central Nervous System Drugs Advisory Committee voted not to recommend approval, and then in an unusual second vote recommended approval.[20][21]

In April 2024, after a disappointing phase III trial of the medication failed to produce significant differences versus a placebo,[22] Amylyx announced they would begin the process of withdrawing Albrioza and Relyviro from the North American market.[11][23]

Economics

edit

In the United States, healthcare insurer Cigna decided, in 2023, to reverse its prior decision to cover the cost of the medication for all ALS patients, opting instead to cover "patients who meet certain clinical criteria", arguing that the drug is "experimental, investigational or unproven".[24]

Following the earlier announcement of plans to potentially withdraw the medication, the Institute for Clinical and Economic Review criticized the company for pricing the drug at $158,000 per year of treatment, given the uncertainty.[25]

Research

edit

It is being studied as a treatment for Wolfram syndrome and progressive supranuclear palsy, despite the withdrawal of North American marketing authorization for amyotrophic lateral sclerosis (ALS).[11]

References

edit
  1. ^ a b "Qualifying notice for Albrioza". Health Canada. 13 June 2022. Archived from the original on 14 June 2022. Retrieved 13 June 2022.
  2. ^ a b c d e "Albrioza monograph" (PDF). 1 June 2022. Archived (PDF) from the original on 14 June 2022. Retrieved 14 June 2022.
  3. ^ "Summary Basis of Decision (SBD) for Albrioza". Health Canada. 23 October 2014. Archived from the original on 24 January 2023. Retrieved 24 January 2023.
  4. ^ a b c "Relyvrio- sodium phenylbutyrate/taurursodiol powder, for suspension". DailyMed. 30 September 2022. Archived from the original on 16 October 2022. Retrieved 16 October 2022.
  5. ^ a b c "Drug Approval Package: Relyvrio". U.S. Food and Drug Administration (FDA). 27 October 2022. Archived from the original on 18 November 2022. Retrieved 18 November 2022.
  6. ^ a b c d "AMX0035". alsnewstoday. Archived from the original on 28 May 2021. Retrieved 15 June 2021.
  7. ^ a b c d e "FDA Approves New Treatment Option for Patients with ALS". U.S. Food and Drug Administration (FDA) (Press release). 29 September 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.   This article incorporates text from this source, which is in the public domain.
  8. ^ "Amylyx Pharmaceuticals Announces Health Canada Approval of Albrioza for the Treatment of ALS" (Press release). Amylyx. 13 June 2022. Archived from the original on 14 June 2022. Retrieved 13 June 2022.
  9. ^ "Amylyx Pharmaceuticals Announces FDA Approval of Relyvrio for the Treatment of ALS". Amylyx (Press release). 29 September 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
  10. ^ "Amylyx's ALS drug knocked back again in Europe". BioPharma Dive. Archived from the original on 19 January 2024. Retrieved 12 February 2024.
  11. ^ a b c "Amylyx Pharmaceuticals Announces Formal Intention to Remove Relyvrio/Albrioza from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy". Amylyx Pharmaceuticals. 4 April 2024. Archived from the original on 4 April 2024. Retrieved 5 April 2024 – via Business Wire.
  12. ^ Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. (September 2020). "Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis". The New England Journal of Medicine. 383 (10): 919–930. doi:10.1056/NEJMoa1916945. PMC 9134321. PMID 32877582.
  13. ^ Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. (January 2021). "Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis". Muscle & Nerve. 63 (1): 31–39. doi:10.1002/mus.27091. PMC 7820979. PMID 33063909.
  14. ^ "Novel ALS Drug Continues to Show Survival Benefit". medpagetoday.com. 19 April 2021. Archived from the original on 19 May 2021. Retrieved 15 June 2021.
  15. ^ Paganoni S, Hendrix S, Dickson S, Knowlton N, Macklin E, Cohen J, et al. (13 April 2021). "Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS (4550)". Neurology. 96 (15 Supplement). doi:10.1212/WNL.96.15_supplement.4550. S2CID 266100302. Archived from the original on 13 August 2021. Retrieved 15 June 2021.
  16. ^ "Long-term survival outcomes of AMX0035 for ALS". 22 April 2021. Archived from the original on 14 June 2022. Retrieved 15 June 2021.
  17. ^ "AMX0035 Meets Primary Safety and Tolerability End Point in Alzheimer Disease". Neurology live. 17 November 2021. Archived from the original on 21 November 2021. Retrieved 9 April 2022.
  18. ^ "AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) (CENTAUR)". ClinicalTrials.gov. 25 April 2017. Archived from the original on 23 September 2022. Retrieved 29 September 2022.
  19. ^ Belluck P (8 March 2024). "A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market". The New York Times. ISSN 0362-4331. Archived from the original on 9 March 2024. Retrieved 9 March 2024.
  20. ^ "ALS drug's approval draws cheers from patients, questions from skeptics". NPR. 30 September 2022. Archived from the original on 1 October 2022. Retrieved 30 September 2022.
  21. ^ Howard J (29 September 2022). "ALS drug gets FDA approval despite uncertainty about effectiveness". CNN. Archived from the original on 29 September 2022. Retrieved 30 September 2022.
  22. ^ "Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS". 8 March 2024. Archived from the original on 8 March 2024.
  23. ^ "Dear health care professional letter: Albrioza". Health Canada. 20 June 2024. Retrieved 21 June 2024.
  24. ^ Bell J (7 February 2023). "Cigna restricts coverage of new ALS drug, deepening fears about access". BiopharmaDive. Archived from the original on 8 February 2023. Retrieved 11 February 2023.
  25. ^ Saltzman J (8 March 2024). "In Setback for ALS Patients, Cambridge Biotech's Drug Fails Clinical Trial, Could Be Withdrawn From Market". The Boston Globe. Archived from the original on 8 March 2024. Retrieved 9 March 2024.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sodium_phenylbutyrate/ursodoxicoltaurine&oldid=1230287976"